Abingdon Health PLC Director/PDMR Shareholding (3299W)
21 December 2021 - 7:40PM
UK Regulatory
TIDMABDX
RNS Number : 3299W
Abingdon Health PLC
21 December 2021
21 December 2021
Abingdon Health plc
("Abingdon" or "the Company")
Director/PDMR Dealings
York, U.K. 21 December 2021: Abingdon Health plc (AIM: ABDX), a
leading international developer and manufacturer of high quality
and effective rapid tests, confirms the participation of certain
Directors in the Second Placing, pursuant to the Fundraising
announced on 1 December 2021.
Director Participation in the Placing
Participating Number of Number of Number of Percentage
Director Existing Placing Shares Ordinary of Enlarged
Ordinary subscribed Shares held Share Capital
Shares for in the following on Admission
Placing Second Admission
Dr Christopher
Hand 11,228,868 999,599 12,228,467 10.0%
----------- ---------------- ------------------ ---------------
Chris Yates 6,513,844 1,000,000 7,513,844 6.2%
----------- ---------------- ------------------ ---------------
Concert Party Interests
Following completion of the Fundraising, the interests of the
Concert Party have reduced to 35.8 per cent. of the Company's total
voting rights.
Capitalised terms used in this announcement shall have the same
meanings as defined in the Circular sent to Shareholders and
available to view on the Company's website, as published by the
Company on 2 December 2021.
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross , Chief Financial Officer
Christopher Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000
Nominated Adviser)
Shaun Dobson, Peter Steel, Alex Bond (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Mob: +44 (0)7980 541 893 / +44 (0)77867
Marriage 984 082
Alice Woodings Mob: +44 (0)7407 804 654
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of
high-quality rapid tests across all industry sectors, including
healthcare and COVID-19. Abingdon is the partner of choice for a
growing global customer base and takes projects from initial
concept through to routine and large-scale manufacturing and has
also developed and marketed its own labelled tests.
The Company offers product development, regulatory support,
technology transfer and manufacturing services for customers
looking to develop new assays or transfer existing laboratory-based
assays to a lateral flow format. Abingdon Health aims to support
the increase in need for rapid results across many industries and
locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R) , a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Chris Yates
-------------------------------------------- -------------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------------------------- -------------------------------------------------------
b) Initial notification Initial Notification
/Amendment
-------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------------------------
a) Name Abingdon Health plc
-------------------------------------------- -------------------------------------------------------
b) LEI 213800XFI4WV3FBILO20
-------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.025 pence each
financial instrument,
type of instrument
Identification code GB00BLF79J41
b) Nature of the transaction Purchase of Ordinary Shares
-------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s)
---------------------------------------- ----------
Price(s) Volume(s)
---------------------------------------- ----------
25.00 pence 1,000,000
------------------------------------------------------------------------------------------ ----------
d) Aggregated information N/A - Single transaction
e) Date of the transaction 21 December 2021
-------------------------------------------- -------------------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------------- -------------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Christopher Hand
-------------------------------------------- -------------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------------------------------
a) Position/status Chairman
-------------------------------------------- -------------------------------------------------------
b) Initial notification Initial Notification
/Amendment
-------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------------------------
a) Name Abingdon Health plc
-------------------------------------------- -------------------------------------------------------
b) LEI 213800XFI4WV3FBILO20
-------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.025 pence each
financial instrument,
type of instrument
Identification code GB00BLF79J41
b) Nature of the transaction Purchase of Ordinary Shares
-------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s)
---------------------------------------- ----------
Price(s) Volume(s)
---------------------------------------- ----------
25.00 pence 999,599
------------------------------------------------------------------------------------------ ----------
d) Aggregated information N/A - Single transaction
e) Date of the transaction 21 December 2021
-------------------------------------------- -------------------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------------- -------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHVFLBLFLLXFBV
(END) Dow Jones Newswires
December 21, 2021 03:40 ET (08:40 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2023 to Apr 2024
